Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research

Abstract LB-222: Identification of rare KRAS codons 12 and 13 mutations by shifted termination assay

Howard Doong, Xiaofei Li, Caifu Chen and Julian Walker
Howard Doong
1TrimGen Corporation, Sparks, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofei Li
1TrimGen Corporation, Sparks, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caifu Chen
2Applied Biosystems, Foster City, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julian Walker
2Applied Biosystems, Foster City, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-LB-222 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

We have developed a sensitive and specific method for research studies, using Shifted Termination Assay (STA) to detect 12 possible KRAS mutations in codons 12 and 13. In this study, we analyzed 118 samples collected from formalin-fixed and paraffin-embedded (FFPE) metastatic colorectal cancer tumors.

The detection method includes carrying out a primer extension reaction in the presence of a wild-type DNA sequence. The primer extension reaction is stopped when encountered by a mutated base. If no mutation is detected the reaction terminates at the next nucleotide resulting in a large wild-type fragment. This creates a shift in the amount of labeled nucleotides incorporated on the primer extended product, and is then differentiated by fragment analysis using Applied Biosystems capillary electrophoresis systems.

Among the 118 samples tested, 32 were found to carry a mutation with 9 different variants. The most common mutations found in codon 12 were GGT>TGT (G12C, 9/32) and GGT>GTT (G12V, 8/32). Two rare variants in codon 12, GGT>GCT (G12A, 1/32) and GGT>CGT (G12A, 1/32), were also observed. For codon 13, the most common mutation found in the samples was GGC >GAC (G13D). In this study, we found 4 variants with 3 different types - 2 samples of GGC>AGC (G13S), 1 sample of GGC>GAC (G13D) and 1 sample of GGC>CGC (G13R). In summary, our data suggest that more KRAS mutations were observed in codon 13 relative to codon 12 in research samples, and the STA assay is an easy to use, robust method to detect possible KRAS mutations in codons 12 & 13. STA is currently for research use only, not for use in diagnostic procedures.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-222.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-222: Identification of rare KRAS codons 12 and 13 mutations by shifted termination assay
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract LB-222: Identification of rare KRAS codons 12 and 13 mutations by shifted termination assay
Howard Doong, Xiaofei Li, Caifu Chen and Julian Walker
Cancer Res April 15 2010 (70) (8 Supplement) LB-222; DOI: 10.1158/1538-7445.AM10-LB-222

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-222: Identification of rare KRAS codons 12 and 13 mutations by shifted termination assay
Howard Doong, Xiaofei Li, Caifu Chen and Julian Walker
Cancer Res April 15 2010 (70) (8 Supplement) LB-222; DOI: 10.1158/1538-7445.AM10-LB-222
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research

  • Abstract SY20-03: Novel radiotracers for clinical molecular imaging in oncology
  • Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy
  • Abstract SS02-04: How much can we afford to pay for new drugs, and how do we make those decisions?
Show more 3

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-244: Implication of secretory mucin MUC5AC and its glycan modification for detection of pancreatic cancer
  • Abstract LB-253: Novel prognostic gene profiles in tumors for breast cancer survival
  • Abstract LB-263: P53 promotes replication genome stability by epigenetics-enabled MRE11 restart
Show more 3

Late-Breaking Poster Presentations - Biomarkers Predictive of Benefit from Therapy

  • Abstract LB-221: Differential aberrant DNA methylation predicts for Tarceva response in NSCLC
  • Abstract LB-220: Molecular predictors of sensitivity to an IGF1R inhibitor in pre-clinical models of lung and colon cancers
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement